Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas. Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.

Trial Details

NCT ID
NCT05891821
Phase
PHASE2
Sponsor
Immune Oncology Research Institute
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Balstilimab
Locations (sample)
  • Yerevan, Armenia|40.17765,44.5126

Key Eligibility Criteria

  • Voluntarily agree to participate by giving written informed consent
  • ≥ 18 years of age
  • Have a histologically confirmed diagnosis of a relapsed/refractory classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL) …
  • Has a life expectancy of at least 3 months and an ECOG performance status of ≤1 as determined by study Investigator

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →